Guardant Health Fda Approval

Listing Websites about Guardant Health Fda Approval

Filter Type:

Guardant Health, Inc. - Guardant Health receives FDA approval for

(9 days ago) WEB“This FDA approval is great news for breast cancer patients with ESR1 mutations, who now have, for the first time, an approved treatment for their specific type of cancer and a blood-based companion diagnostic,” said Helmy Eltoukhy, Guardant …

https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-receives-FDA-approval-for-Guardant360-CDx-as-companion-diagnostic-for-Menarini-Groups-ORSERDU-for-treatment-of-patients-with-ESR1-mutations-in-ER-HER2--advanced-or-metastatic-breast-cancer/default.aspx

Category:  Cancer Show Health

MCGP May 23, 2024 FDA Executive Summary

(1 days ago) WEBOn March 10, 2023, Guardant Health, Inc. submitted a Premarket approval application (PMA) requesting approval of the class III device under Pxxxxxx. This …

https://www.fda.gov/media/178792/download

Category:  Health Show Health

Guardant Health, Inc. - Guardant Health Receives FDA Approval for

(3 days ago) WEBBlood test provides simple way to test patients comprehensively for tumor alterations that drive selection of targeted therapies, now including ENHERTU Guardant …

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-Daiichi-Sankyo-and-AstraZenecas-ENHERTU-for-Treatment-of-NSCLC-Patients-With-Activating-HER2-Mutations/default.aspx

Category:  Health Show Health

Guardant360 CDx - P200010/S010 FDA

(9 days ago) WEBGuardant360 CDx is a laboratory test for detecting gene mutations in cfDNA. This approval is for detecting ESR1 missense mutations in patients with breast cancer.

https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s010

Category:  Cancer Show Health

Guardant Health Receives FDA Approval for Guardant360® CDx as …

(5 days ago) WEBGuardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment …

https://webmail.guardanthealth.com/2022/08/12/guardant-health-receives-fda-approval-for-guardant360-cdx-as-companion-diagnostic-for-daiichi-sankyo-and-astrazenecas-enhertu-for-treatment-of-nsclc-patients-with-activating-her2/

Category:  Health Show Health

Guardant360® CDx: Fastest FDA-Approved Liquid CGP Panel

(7 days ago) WEBGuardant360® CDx is the fastest FDA-approved CGP panel for all advanced solid tumors including lung, breast, and colorectal cancers. Results in less than 7 days.

https://www.guardantcomplete.com/products/guardant360-cdx

Category:  Cancer Show Health

Blood test to detect colon cancer could move a step closer to FDA

(2 days ago) WEBGuardant Health’s Shield tests could be the first approved blood screening test for colorectal cancer that meets requirements for Medicare reimbursement.

https://www.cnn.com/2024/05/23/health/colon-cancer-blood-test/index.html

Category:  Cancer Show Health

FDA approves Guardant's tumor-sequencing blood test …

(8 days ago) WEBGuardant Health received a milestone approval from the FDA for its cancer test, as the first liquid biopsy able to genetically profile solid tumors anywhere in the body through a single blood draw.

https://www.fiercebiotech.com/medtech/fda-approves-guardant-s-next-gen-tumor-sequencing-blood-test

Category:  Cancer Show Health

What to know about the blood test to detect colon cancer …

(1 days ago) WEBGuardant Health, the company that makes Shield, is seeking FDA premarket approval for the test to screen for colorectal cancer among people aged 45 …

https://abcnews.go.com/Health/blood-test-detect-colon-cancer-recommended-fda-panel/story?id=110531552

Category:  Cancer Show Health

FDA Approves Blood Tests That Can Help Guide Cancer …

(3 days ago) WEBFDA has recently approved two liquid biopsy tests, the Guardant360 CDX and FoundationOne Liquid CDX. Using a blood sample, the tests identify genetic changes in DNA shed by tumors. Doctors can …

https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-guardant-360-foundation-one-cancer-liquid-biopsy

Category:  Health Show Health

Guardant Health colon cancer test endorsed by FDA advisory …

(1 days ago) WEBAn independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer …

https://www.statnews.com/2024/05/23/guardant-fda-shield-colon-cancer-blood-screening-panel-recommend/

Category:  Food,  Cancer Show Health

Guardant Health, Inc. - Guardant360® CDx Receives FDA Approval …

(5 days ago) WEBGuardant Health blood test identifies patients with EGFR exon 20 insertion mutations who may benefit from targeted treatment with RYBREVANT™ after …

https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-Companion-Diagnostic-for-Janssens-RYBREVANT-amivantamab-vmjw-for-Use-in-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer-with-EGFR-Exon-20-Insertion-Mutations/default.aspx

Category:  Health Show Health

FDA Approves Guardant Health’s CDx Liquid Biopsy for Breast …

(3 days ago) WEBThe FDA approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for metastatic breast cancer patients with ESR1 mutations.

https://clpmag.com/disease-states/cancer/breast/fda-approves-guardant-healths-cdx-liquid-biopsy-for-breast-cancer-patients/

Category:  Cancer Show Health

FDA Approves First Liquid Biopsy Next-Generation Sequencing …

(7 days ago) WEBToday, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) …

https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test

Category:  Food Show Health

FDA Advisory Panel Review of Guardant Health’s Shield™ Blood …

(Just Now) WEBPALO ALTO, Calif., April 22, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics …

https://finance.yahoo.com/news/fda-advisory-panel-review-guardant-125200837.html

Category:  Health Show Health

Tests for Patients with Early and Advanced Stage Cancer

(4 days ago) WEBGuardant Reveal is a completely tissue-free test that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early-stage colorectal, …

https://testnewsite.guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/

Category:  Health Show Health

FDA Panel Gives Nod to Blood Test for Colon Cancer

(5 days ago) WEBGuardant’s application for approval was based on a study that showed the test detected 83% of colon cancers, according to the FDA documents.

https://www.healthday.com/health-news/cancer/fda-panel-gives-nod-to-blood-test-for-colon-cancer

Category:  Cancer Show Health

First liquid biopsy to receive FDA Approval… - Guardant Health …

(9 days ago) WEBFor Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Currently, the liquid biopsy is …

https://www.guardanthealthamea.com/first-liquid-biopsy-to-receive-fda-approval/

Category:  Health Show Health

Guardant Health, Inc. - Guardant Health Announces Tentative Date …

(5 days ago) WEBGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and …

https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-Announces-Tentative-Date-of-FDA-Advisory-Panel-Review-of-Shield-Blood-Test/default.aspx

Category:  Food Show Health

Guardant Health, Inc. - Guardant360® CDx Receives FDA Approval …

(1 days ago) WEBGuardant Health liquid biopsy can help identify the 13 percent of patients harboring the KRAS G12C mutation, a previously undruggable target, who may be …

https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-First-and-Only-Liquid-Biopsy-Companion-Diagnostic-for-Amgens-LUMAKRAS-sotorasib-KRASG12C-Inhibitor-for-Use-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx

Category:  Health Show Health

Guardant360 CDx – P200010/S002 FDA

(9 days ago) WEBThis approval expands the indications for use of the Guardant360 CDx test to include an additional mutation (KRAS G12C) as a target for treatment options for …

https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s002

Category:  Health Show Health

Guardant Health slips as FDA comments on cancer screening test

(3 days ago) WEBGuardant Health ( NASDAQ: GH) shares turned lower on Tuesday after FDA staffers commented on its Shield blood test for colorectal cancer screening (CRC) ahead of an …

https://www.msn.com/en-us/health/other/guardant-health-slips-as-fda-comments-on-cancer-screening-test/ar-BB1mN1ba

Category:  Cancer Show Health

Guardant Health, Inc. - Guardant Health submits premarket …

(2 days ago) WEBGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug …

https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-submits-premarket-approval-application-to-the-U.S.-Food-and-Drug-Administration-for-Shield-blood-test/default.aspx

Category:  Food Show Health

US FDA staff says Guardant's cancer test may fail to detect some …

(9 days ago) WEBThe U.S. Food and Drug Administration's staff reviewers on Tuesday raised concerns that Guardant Health's blood test for a cancer of colon or rectum may fail to …

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-says-guardants-cancer-test-may-fail-detect-some-tumors-2024-05-21/

Category:  Food,  Cancer Show Health

Filter Type: